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CLINICAL ARTICLE
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OBJECTIVE Pediatric epilepsy is characterized as drug resistant in 20%–30% of patients and defined as persistent
seizures despite adequate treatment with two first-line antiepileptic medications. The American Academy of Neurology
advocates surgical options earlier in the treatment of epilepsy to provide long-term seizure reduction. The new development of minimally invasive approaches has recently allowed for surgical options to patients not previously deemed surgical candidates. These may include patients with bilateral, deep, eloquent, or poorly localizing epileptogenic foci. To this
end, responsive neurostimulation (RNS) is an FDA-approved closed-loop neuromodulation device for adjuvant treatment
of adults with medically intractable epilepsy arising from one or multiple foci.
METHODS In this study, the authors describe their initial institutional experience with the use of RNS in pediatric
patients with drug-resistant epilepsy. An IRB-approved retrospective review was conducted of 8 pediatric patients who
underwent RNS implantation at Cincinnati Children’s Hospital Medical Center between 2019 and 2021.
RESULTS Eight patients met the inclusion criteria for the study. The average age at the time of surgery was 14.7 years
(range 8–18 years) with a mean follow-up of 16.5 months. All patients underwent invasive monitoring with stereo-EEG,
subdural grid placement, or a combination of both. All patients had either bilateral or eloquent cortex targets. Trajectories
were based on noninvasive (phase 1) and invasive (phase 2) seizure onset zone localization data. Four (50%) of the 8
patients underwent surgical intervention for epilepsy prior to RNS placement. RNS electrodes were placed with robot-assisted guidance in a hybrid operating room with intraoperative CT and electrocorticography. The authors demonstrated
individualized RNS electrode trajectory and placement with targets in the amygdala/hippocampus, bilateral insula, bilateral parietal and occipital targets, and frontoparietal regions for a total of 14 implanted electrodes. One adverse event
occurred, a wound infection requiring return to the operating room for removal of the RNS implant. All patients demonstrated a reduction in seizure frequency. All patients achieved > 50% reduction in seizure frequency at last follow-up.
CONCLUSIONS RNS implantation in carefully selected pediatric patients appears safe and efficacious in reducing
seizure burden with a low rate of operative complications.
https://thejns.org/doi/abs/10.3171/2022.7.PEDS2281
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refractory epilepsy, defined as persistent seizures despite two first-line antiepileptic
medications, is prevalent in 20%–30% of pediatric epilepsy patients.1 The latest guidelines from the American Academy of Neurology now advocate for early consideration of surgical options to provide long-term seizure
reduction more effectively and expeditiously.2 The develedically

opment of minimally invasive surgical approaches allows
options for patients who were previously not considered
to be surgical candidates, particularly those with bilateral,
deep, eloquent, or poorly localizing epileptogenic foci.
Particularly for patients with anatomical overlap between
driver nodes of seizure-generating network and functional
nodes, neuromodulation has emerged as a viable option.

ABBREVIATIONS fMRI = functional MRI; RNS = responsive neurostimulation; SDG = subdural grid; SEEG = stereo-EEG.
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Responsive neurostimulation (RNS) is an FDA-approved closed-loop neuromodulation device for treatment
of medically refractory epilepsy (RNS System, NeuroPace, Inc.). Neurostimulation is the term used to describe
the application of electricity to the CNS with the goal of
reducing seizure frequency and severity. A closed-loop
system senses brain activity based on a predefined seizuredetection algorithm and delivers stimulation based on detected events to abort seizures.3 Heck et al. demonstrated
the safety and efficacy of RNS as an adjunct therapy to
reduce the frequency of seizures in adults with medically
intractable epilepsy as part of a multicenter, double-blinded, sham-stimulation controlled pivotal study.4 Although
RNS was initially conceived to abort seizure activity, it
may also have long-term beneficial effects by altering the
plasticity of relevant neuronal networks. There is evidence
that RNS response is due to indirect prevention rather than
through directed triggered seizure inhibition.5 RNS is currently FDA approved for adults 18 years of age or older.
However, recent case reports have described the off-label
application of RNS in pediatric patients.6,7 In this study,
we report our institutional experience using RNS for various etiologies of medically refractory epilepsy in a complex pediatric population.

Methods

An IRB-approved retrospective review of pediatric
patients who underwent RNS implantation at Cincinnati
Children’s Hospital between 2019 and 2021 was conducted. Each patient was reviewed by the multidisciplinary surgical epilepsy team at Cincinnati Children’s Hospital prior
to consideration of RNS as a treatment option for medically refractory epilepsy. Briefly, if patients are deemed to
have intractable epilepsy by our neurology epilepsy team,
they undergo noninvasive monitoring and testing over a
5-day period that may include video-EEG, MRI of the
brain, PET, SPECT/SISCOM (subtraction ictal SPECT
coregistered with MRI), magnetoencephalography, and
functional MRI (fMRI) as indicated. After discussion of
results at a comprehensive epilepsy surgery conference, a
decision is made for next appropriate management course.
The following variables were collected: age, sex, age at
epilepsy onset, etiology, comorbidities, preoperative seizure frequency, fMRI findings, seizure onset zone, history
of previous surgery, stereo-EEG (SEEG) findings, subdural grid (SDG) placement details and results, localization,
target of implantation, surgical technique, complications,
follow-up, postoperative seizure frequency, and calculation of reduction in seizure frequency (Table 1).
Seizure frequency reduction was based on preoperative
seizure frequency and postoperative seizure frequency recorded in the electronic medical record. Baseline seizure
frequency was reported at the most recent 3-month interval leading to an office visit prior to RNS implantation.
Postoperatively, patients were seen at 1 month for initial
programming and were followed at regular 3-month intervals for reprogramming. Patients were encouraged to
use an online seizure diary and to mark seizures by swiping the provided magnet over the generator whenever possible. Seizure outcome was recorded as seizure frequency
2

as reported by the patient or their family over the most
recent 3-month interval. This measure was compared with
baseline seizure frequency to generate a result for percentage reduction. For patients with multiple seizure types,
the most disabling (typically convulsive) seizure was represented for seizure outcome. Additionally, we reviewed
RNS parameters as established by the neurology team
(Table 2).
Selection of RNS Targets
Localization of the seizure foci and RNS targets was
based on noninvasive data from the phase 1 evaluation and
phase 2 evaluation data from intracranial SDG or SEEG
monitoring in all patients. Figure 1 demonstrates patient 3
as a patient with different modalities used for localization
and treatment. Two patients underwent right-sided SEEG,
2 underwent left-sided SEEG, 5 underwent bilateral
SEEG, and 2 patients underwent SDG placement for invasive monitoring (Table 1). The average number of depth
electrodes placed for SEEG was 13.4 (range 5–16 and a
range of 44–192 contacts), while the 2 patients undergoing
SDG placement had an average of 78 (64 and 92) cortical contacts. Implantation times ranged between 3 and 13
days for all invasive monitoring procedures. No surgical
complications were recorded as a result of invasive monitoring. Four patients were identified as having bilateral
seizure onset zones. Seven patients had at least one eloquent cortex target, including 1 patient who demonstrated
right-sided language localization on fMRI and electrode
stimulation during SEEG (patient 1). Individualized robotguided stereotactic electrode trajectories and targets were
planned to diverse anatomical locations, including the
amygdala/hippocampus, bilateral insula, bilateral parietal
and occipital targets, and a frontoparietal region for a total
of 14 electrodes implanted (Tables 1 and 2).
Surgical Technique
Patients were tested for methicillin-resistant Staphylococcus aureus colonization prior to surgery and underwent
a decolonization protocol if positive. If methicillin-resistant S. aureus results were positive, the antibiotic regimen
included vancomycin in addition to cefazolin for 24 hours
postoperatively. Under normal circumstances, we administered a weight-based dose of cefazolin intraoperatively
prior to incision. Patients were then given 3 doses of cefazolin postoperatively. We used a protocol with total intravenous anesthesia, including a paralytic because of the
need for intraoperative electrocorticography recordings
from the RNS device. Patients were administered antiepileptic medications prior to surgery to prevent intraoperative epileptic events. Intravenous steroids were given at the
time of the first electrode placement. While passing the
electrodes, systolic blood pressure was monitored using an
arterial line and maintained at or slightly below normotension for age. In general, a radiolucent three-point fixation head clamp was used for unilateral targets and a CRW
stereotactic head frame was used for bilateral targets. At
our institution, we use the ROSA (Robotic Surgical Assistant) robot (Zimmer Biomet) for stereotactic guidance.
The incision was planned to accommodate placement of
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laser interstitial thermal therapy; OCD = obsessive-compulsive disorder, PRES = posterior reversible encephalopathy syndrome; pt = patient; s/p = status post; Sz = seizure; VNS = vagus nerve stimulator; VP = ventriculoperitoneal; VSD = ventriculoseptal defect.
* Patient 6 did not have any recordable seizures after RNS implant for 8 months. He had one seizure in the 9th month, and the RNS is currently in detection mode only.
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TABLE 1. Patient cohort demographic data
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TABLE 2. Patient cohort RNS data
Pt No.
1
2
3
4
5
6*
7
8

Lead Location

Electrode Spacing

Rt hippocampus
DL330-10
Lt hippocampus
DL330-10
Bilat occipital
DL330-10
Lt hippocampus & lt occipital
DL330-10
Lt hippocampus & lt parietal
DL330-10
Lt frontoparietal & lt insula
DL330-10
Bilat insula
DL330-10 & DL440-10
Bilat parietal
DL330-10

Bipolar/Cathode or Charge Density
Anode; Lead to Lead
(μC/cm2)
Bipolar
Bipolar
Bipolar
Bipolar
Lead to lead
NA
Bipolar
Bipolar

4.1
2.5
2.5
2.5
0.5
0
1
1

Pattern Detection

Average No. of
Stimulations/Day

Bandpass & line length
Bandpass & line length
Bandpass
Bandpass
Bandpass
Bandpass
Bandpass
Bandpass

3000
2000
2500
4000
400
0
5000
1500

NA = not available.
* Patient 6 did not have any recordable seizures after RNS implant for 8 months. He had one seizure in the 9th month, and the RNS is currently in detection mode only.

the RNS device, as estimated by a nonsterile implant. Ideally, the larger incision made for the generator included at
least one of the planned lead entry points to minimize the
need for multiple incisions on the scalp. Care was taken to
bend the arms of the ferrule to allow the generator to sit
flush with the outer cortex and not produce compression
on the dura mater or to put pressure on the patient’s over-

lying skin. The generator was oriented in a way that also
provided easy access for battery replacement, wherein the
surgeon would only need to reopen a portion of the prior
incision to replace the generator (Fig. 2). Stereotactic depth
electrodes were placed prior to the craniectomy for generator insertion to ensure that accuracy was maintained with
initial positioning and registration (Fig. 3). An intraopera-

FIG. 1. Patient 3. This patient had intractable seizures after severe hypoglycemic insult secondary to hyperinsulinism from islet
cell adenoma. A: Coronal FLAIR sequence MR image demonstrating bioccipital insults. B: Magnetoencephalography source
localization with equivalent current dipole showing sources localizing in the right inferior occipital head region. The electrographic
seizure localized at onset to the right inferior occipital lobe with subsequent spread to the left inferior occipital lobe. Right and left
hemifield visual evoked fields both demonstrated localization to the left occipital lobe. C and D: Ictal SPECT scans. Isotope was
administered 24 seconds after onset of ictal EEG changes from an electroclinical seizure originating from the right occipital region.
E: Functional MR images of visual fields with representation of bioccipital lesions (red) and visual tractography (green). F: Threedimensional CT reconstruction of bilateral SEEG. Ten seizures were recorded during monitoring, 4 with ictal onset localized to the
left O’ electrode and 6 localizing to the right O electrode. G: Three-dimensional CT reconstruction of RNS and final bioccipital lead
placement. Figure is available in color online only.
4
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tive CT scan was obtained to ensure that no intracranial
complications from the lead placement were identified. In
most cases, the surgeries were performed in a hybrid operating room with 3D CT available intraoperatively.

Results

Demographics
Eight patients underwent RNS System implantation at
Cincinnati Children’s Hospital Medical Center between
January 2019 and August 2021. All patients met clinical
criteria for implantation of the RNS System after review
by the multidisciplinary surgical epilepsy team at our institution. Six of 8 patients had private insurance, and their
surgery was approved without additional peer-to-peer review or appeals for denials. The 2 patients without insurance had the cost of the surgery covered by the hospital
as charitable cases. The average patient age at the time of
RNS implantation was 14.7 years (range 8–17 years). As
demonstrated in Table 1, patients had a variety of etiologies of epilepsy, including posterior reversable encephalopathy syndrome, neonatal injury, cortical dysplasia, severe hypoglycemia, CNS vasculitis, neuronal migrational
abnormalities, and 1q21.1 microdeletion. In addition, 7 of
the 8 patients had significant comorbidities unrelated to
seizures, including intraventricular hemorrhage, hydrocephalus, congenital cardiac disease, and pancreatic tumor (Table 1). Four patients (50%) underwent a prior surgical procedure to treat medically refractory epilepsy and
experienced recurrent or residual seizures. These included
1 patient with a vagus nerve stimulator, 2 patients who
underwent craniotomies for seizure focus resection, and
1 patient who underwent laser interstitial thermal therapy.
Surgical Considerations
The mean surgical time for all hybrid operating room
cases was 260 minutes (SD 46.1 minutes). The mean estimated surgical blood loss was 33 ml (SD 27.6 ml). No intraoperative or postoperative transfusions were required.
All leads were accurately placed according to the preoperative plan and confirmed with intraoperative imaging.
Detection and Stimulation Procedures
All patients received an RNS-320Ms model. After implantation, the device was interrogated and placed into
detection-only mode. Using the manufacturer’s suggested
protocol, a “line length” detector, which determines ictal change based on a running sum of distances between
successive points of the electrocorticography time series
within the sliding window of a given size, was used for initial seizure detection. As of the last visit, 6 of the 8 patients
now have detection settings using bandpass filters exclusively to capitalize on the prominent low-voltage beta and
gamma activities commonly present at ictal onset. Two of
8 patients have both bandpass and line length detectors enabled. Stimulation was initiated once clear seizures were
recorded, typically at 1 month postoperatively, although
in 2 cases this was delayed. For 1 patient, stimulation
was delayed until 3 months postoperatively after seizures
were recorded. For patient 6, lack of clarity about discrete
seizures postimplantation has resulted in an order for a

FIG. 2. Intraoperative photograph of right-sided RNS placement with
the lead inserted into the hippocampus from a posterior approach.
Note the placement of the RNS System within the exposure, which will
allow replacement of the unit without reopening the whole incision and
reduced risk to severing the lead inadvertently. Figure is available in
color online only.

video-EEG, and stimulation was withheld for 8 months. In
the 9th month, the patient had a clinical seizure and detection was enabled at that time. He is currently not undergoing stimulation. For all other patients, stimulation was
started at 0.5 μC/cm2, pulse width of 160 μsec, duration
of 100 msec, and frequency of 200 Hz. Every 3 months,
detection was adjusted as needed to capture the earliest
ictal change, and charge density was increased by 0.5 μC/
cm2 as indicated for continued seizures, up to a maximum
of 4 μC/cm2. The stimulation field was bipolar, adjacent
contact, in 5 of the 7 patients undergoing stimulation. The
other 2 patients had lead-to-lead stimulation to provide a
more diffuse applied electrical field. In the 7 patients undergoing stimulation, the average number of stimulations
per day was 2629 (Table 2).
Surgical Complications After RNS Placement
One adverse event occurred in our series. A patient
developed erythema and drainage from the cranial flap
2 weeks after surgery. Cultures were obtained from the
wound, and these were positive for Pseudomonas aeruginosa. The patient was then taken to the operating room
for complete removal of the RNS System. After a 6-week
course of intravenous antibiotics was completed, the patient was brought back to the operating room for reimplantation of the RNS System. At the time of the latest followup, there were no further complications, and the patient
benefited from a reduction in seizure frequency.
J Neurosurg Pediatr August 26, 2022
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FIG. 3. A: Patient 3. Bilateral posterior quadrant stereo-electroencephalogram with selected contacts shown at ictal onset of a
typical event (red oval). Right hemisphere electrodes are shown in the upper half, and left hemisphere electrodes appear in the
lower half. Bipolar recording montage with a 1-Hz low-frequency and no high-frequency filter. At seizure onset, a band of lowvoltage gamma activity was present in the right occipital pole (O6–10) contacts, followed by spread to other right occipital cortex
(L electrode in Fig. 1) and left occipital spiking (O’5–9). Note the absence of fast frequency activity of ictal morphology in the
left hemisphere. Rhythmic spiking best developed in ictal onset contacts O6–10. B: Intraoperative recording of newly implanted
electrodes, with the left occipital montage in the upper half and the right occipital montage in the lower half. Lateral right occipital
contact complex spike morphology is shown (green oval). C: Typical recording from the extraoperative RNS device, demonstrating ictal onset and spread consistent with previously seen seizures recorded on SEEG. Diminution of interictal discharges and
development of gamma activity were seen in the lateral right occipital montage (ROcc3–4) at ictal onset (brown oval), followed by
rapid spread to the left hemisphere and best spike development in ROcc3–4 (consistent with the O6–10 target region on SEEG).
Tx flags indicate stimulation therapy for seizure detection. Figure is available in color online only.

Follow-Up and Seizure Outcomes
Follow-up for our group of patients ranged between 7
and 39 months with an average follow-up period of 16.5
months. All patients achieved > 50% reduction in their seizure frequency (Table 1). The mean reduction in seizure
frequency was 84.4% (SD 14%).

Discussion

Managing medically refractory epilepsy in pediatric
patients remains a challenge for epileptologists and epilepsy surgeons alike. This is particularly true in pediatric patients who have a difficult-to-localize seizure focus,
multiple and/or bilateral foci, or eloquent localization, or
in whom previous surgical therapy has failed. In our initial experience with RNS, we applied concepts previously
described in the adult epilepsy surgery literature to one
of the most difficult groups of patients evaluated by our
comprehensive epilepsy surgery team.7,8 Our case series
demonstrates the safety and effectiveness of off-label RNS
System implantation in the pediatric population, as previously reported in the literature. The RNS System was successfully implanted in all 8 pediatric patients.
Our patient population provides a broader range of
seizure foci targets than previously reported in the pediatric literature.9–13 These include not only mesial temporal structures but also bilateral frontal, parietal, occipital, and insular targets, thus expanding the potential use
of RNS for various seizure foci. Targets were identified
prior to RNS implantation using noninvasive and invasive
monitoring with SDG and/or SEEG implantation to best
6

characterize the epilepsy network and identify targetable
seizure onset zones. Ultimately, SEEG was the modality
used to identify the specific targets implanted. Our series
also demonstrates the usefulness of RNS as an option for
patients who underwent prior surgical interventions that
were unsuccessful at effectively controlling seizures. The
RNS System, therefore, can be included as part of a comprehensive treatment strategy for medically refractory
epilepsy and can be performed in combination with other
surgical and medical treatment strategies safely. Clinical
decision-making leading to RNS implantation over other
neuromodulatory brain stimulation devices (vagus nerve
stimulators or deep brain stimulators) at our center involves a multidisciplinary assessment of invasive monitoring data and eloquent cortex identification. Patients with
one to two well-delineated seizure networks on SEEG, for
which one or both foci are in eloquent cortex, are deemed
the best candidates for RNS implantation.
All 8 patients in our series experienced at least a 50%
reduction in seizures from their preoperative baseline
(mean 84.4%). The early positive response combined with
the established literature demonstrating increasing efficacy of RNS over time are favorable factors suggesting that
RNS is a useful tool in pediatric epilepsy management.14,15
Treatment with the RNS System is primarily modulatory rather than ablative and can be modified with time
and maturation of the brain. Improvements with time in
response to RNS therapy have also been observed.5,11,15,16
The effect may be due to neuroplasticity, a feature that
may be particularly effective in developing brains. We expect that with further modulation and a longer temporal
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perspective, our patients may continue to demonstrate improvement in seizure outcomes.
Optimal parameters for neuromodulation are currently
unknown. Therefore, for detection and stimulation settings, we have found that starting with parameters similar
to those used in adult clinical trials seems successful in our
pediatric population. It has become our practice to maximize beta and gamma frequency detection early while
programming, to capture the “buzz” seen at ictal onset in
the majority of our population. Hence, we have used bandpass filters more often than line length detectors. It is possible that bandpass filters, which detect root-mean-square
amplitude, may be more sensitive for power modulations
of shorter duration compared with line length detectors.17
There are three potential mechanisms by which pediatric
patients may benefit from RNS: 1) a microlesional effect
resulting in disruption of tissue and disabling the epileptic network, 2) “responsive” stimulation adapting targeted
stimulation to peri-ictal waveform detection, and 3) neuromodulation. The 8-month seizure freedom noted in patient 6 may be due to a microlesional effect secondary to
surgical implantation. Microlesional effects have also been
reported in deep brain stimulator implantation with a reduction in tremor or even after SEEG implantation with a
reduction in seizures without further ablation, stimulation,
or resection.18 The microlesional effect is hypothesized to
be the result of a neuroinflammatory activation of astrocytes and microglia in animal models.19 The potential dynamic of these three mechanisms should be an active area
of study in future.
Our early experience indicates that pediatric RNS has
a dynamic effect on the individual patient. As a guideline,
we recommend that all patients undergo pre- and postsurgical neuropsychological examination. These data will
be included in a larger analysis, as follow-up is currently
ongoing. We hypothesize that working memory and processing speed may improve with improved seizure control,
although potential negative effects of neurostimulation in
different brain regions have not been sufficiently explored.
We experienced one complication of a deep wound infection requiring return to the operating room for explant
of the RNS System. After the system was explanted and
the patient was treated with an appropriate course of intravenous antibiotics, the RNS System was successfully
reimplanted using the patient’s previously achieved detection and stimulation settings. We used the same craniectomy site for the reimplantation. The infection did not recur,
and the implant was able to be used successfully with a
reduction in the patient’s seizures. Despite targeting eloquent areas, no adverse RNS events occurred in our patient cohort. As a small retrospective review, this work is
not without limitations. Results may have been affected by
patient selection bias and relatively short follow-up as well
as partially relying on patient diaries for determination of
seizure outcomes.

Conclusions

Our small retrospective pediatric series of carefully selected patients highlights recent advances specifically in
SEEG and RNS technology that have advanced the field of

pediatric epilepsy surgery. Patients, who not long ago may
not have been considered surgical candidates, are now enjoying significant reductions in disabling seizures.
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